Dragonfly Therapeutics, Inc.’s Post

We have recently entered clinical trial collaboration with Roche to evaluate the combination of our HIF2a inhibitor NKT2152 with standard-of-care (atezolizumab and bevacizumab) in first line advanced HCC. This marks a promising initial stride toward broadening the therapeutic scope of our HIF2a inhibitor, NKT2152, in solid tumors beyond ccRCC. https://lnkd.in/gJk8zKYu

Delivering a Cancer Resolution for the Ones Left Unattended by Current Treatments https://lnkd.in/gQFSZB6s Iovance Biotherapeutics, Inc. FDA #Oncology, #DrugDevelopment, #DrugDiscovery, #Therapy, #ClinicalTrialManagement, #MedicalResearch, #ImmunityManagement, #Biotech, NgocDiep (Diep) Le, MD, PhD #Biotherapeutics, #Medical, #Healthcare, #PatientManagement, #TumorManagement, #RNA

Today we announced that the first patient has been dosed in our Phase 1 trial of IAM1363, a highly selective, brain-penetrant HER2 inhibitor for the treatment of advanced solid tumors and designed to inhibit both wild-type and common HER2 mutants. IAM1363 is Iambic’s first candidate to enter the clinic from our AI-driven drug discovery platform, an important milestone and demonstration of the potential to use AI technologies to rapidly advance highly differentiated treatment options in oncology and other disease areas where new medicines are urgently needed. Today’s news announcement can be found here: https://lnkd.in/gkUS_-U3 #drugdiscovery #cancerresearch #artificialintelligence #clinicaltrials

Did you know that brain metastases (MeTs) are a significant concern in non-small cell lung cancer (NSCLC)? 🧠🔍 Studies estimate that 10% to 30% of NSCLC patients will develop brain MeTs during their disease journey. This alarming statistic highlights the importance of early detection and innovative treatment strategies to improve outcomes for those affected. #NSCLC #BrainMetastases #CancerAwareness #EarlyDetection #InnovativeTreatment #LungCancer #CancerResearch #Oncology #Healthcare #MedicalAdvances #PatientCare #CancerSupport #Survivorship #CancerPrevention #ClinicalTrials #CancerTreatment #OncologyNurses #CancerWarriors #FightCancer #CancerSurvivors #LungHealth #CancerJourney #CancerCommunity #MedicalOncology #RadiationOncology #TargetedTherapy #Immunotherapy #HealthInnovation #CancerAdvocacy"

AstraZeneca is heading towards approval of their leading Antibody-Drug Conjugate (Enhertu) for all solid tumors that are HER2+. This would be the first ADC with a "tumor agnostic" indication. This would represent a breakthrough for AZ certainly, but more importantly for patients who have unresectable / metastatic tumors with little to no option for treatment. Biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers are all potentially treatable with significant improvements to survival benefits. AZ's partner with this ADC - Daiichi - has more promising products in the pipeline, with Merck earlier this year plunking down several billion to get involved. https://lnkd.in/ggu9qSS8

AbelZeta announces an agreement with AstraZeneca to co-develop a novel CAR-T treatment for solid tumors in China. 🩺Hepatocellular carcinoma (HCC) is a huge concern in China, with thousands of new cases annually; about 45% of worldwide HCC deaths occur in Greater China. 👏CEO of AbelZeta: "The treatment of advanced HCC has always been a great challenge, and I believe this CAR-T therapy has the potential to redefine therapeutic paradigms in HCC and other GPC3-expressing solid tumors." #CancerResearch #Innovation #HealthcareCollaboration #CellTherapy

Looking for a suitable in vivo #efficacy model to accelerate 🚀 your anticancer development? 👉Tap into our broad experience in #oncology efficacy studies for NCEs, biologics, and cell-based therapies. Our customized services meet your needs at every phase of your drug development journey. 👉Explore our extensive platform of in vivo tumor models and over 100 human cancer cell lines. Take advantage of our #orthotopic and #bioluminescent models for more effective and close-to-human tumor growth evaluation. Stay ahead with our #syngeneic, #humanized, and immunotherapy-tailored mouse models. 🔗Partner with Accelera for robust efficacy assessments and unlock the future of drug development today! ✉Contact our experts at [email protected] accelera.org #DrugEfficacy #DrugDevelopment #AnticancerDrug #NCE #biologics #cellbasedtherapy #CRO #nonclinical

Ready to dive into your anticancer efficacy assessment? Accelera - Part of NMS Group has the models and expertise to get your drug molecule moving forward 🚀

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial https://lnkd.in/ep2CdfjZ

#Bispecific #Ivonescimab #NSCLC #PD-1 #VEGF Akeso ---Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase III Clinical Trial in NSCLC --Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Trial Conducted by Akeso --PFS Improvement Was Observed Broadly in Patients Across Subgroups, including PD-L1 Low and PD-L1 High Expressing Tumors, Squamous and Non-Squamous Histologies --- Ivonescimab is a bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule https://lnkd.in/grurkhXF